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Abstract
Calcium nephrolithiasis is one of the most common causes of renal stones. While the prevalence of this disease has
increased steadily over the last 3 decades, its pathogenesis is still unclear. Previous studies have indicated that a genetic
polymorphism (rs17251221) in the calcium-sensing receptor gene (CASR) is associated with the total serum calcium levels. In
this study, we collected DNA samples from 480 Taiwanese subjects (189 calcium nephrolithiasis patients and 291 controls)
for genotyping the CASR gene. Our results indicated no significant association between the CASR polymorphism
(rs17251221) and the susceptibility of calcium nephrolithiasis. However, we found a significant association between
rs17251221 and stone multiplicity. The risk of stone multiplicity was higher in patients with the GG+GA genotype than in
those with the AA genotype (chi-square test:P=0.008;odds ratio = 4.79;95% confidence interval, 1.44–15.92;Yates’
correction for chi-square test:P=0.013). In conclusion, our results provide evidence supporting the genetic effects of CASR
on the pathogenesis of calcium nephrolithiasis.
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Introduction
Nephrolithiasis is a worldwide health problem that affects
almost all populations. In Taiwan, its prevalence is approximately
9.6% (14.5% in males and 4.3% in females) [1]. The cause of
nephrolithiasis is still unclear. Environmental factors such as
lifestyle, obesity, and dietary habits seem to be involved in its
development [2], but its pathogenesis may also be influenced by
hormonal, genetic, or anatomical factors [3]. Previous studies have
indicated that genetic polymorphisms of the calcium-sensing
receptor (CASR), vitamin D receptor, and osteopontin genes are
highly associated with stone formation [4]. Therefore, genetic
polymorphisms are important for susceptibility to this disease [4].
Hypercalciuria is one of the main risk factors for nephrolithiasis.
Most patients with nephrolithiasis have calcium-containing stones
[5]. Therefore, the physiological processes that influence calcium
delivery to the kidney may influence stone formation. Perturba-
tions in calcium homeostasis are considered the most important
risk factors for calcium nephrolithiasis [6]. The CASR located in
the plasma membrane of renal tubule cells is a vital regulator of
cellular calcium homeostasis [7]. A previous study has shown that
an inactivating mutation of CASR causes familial hypocalciuric
hypercalcemia (FHH), which leads to life-long hypercalcemia [8].
In addition, a CASR genetic polymorphism (rs17251221) is stron-
gly associated with serum calcium concentration in individuals of
European and Indian-Asian descent [9]. However, the genetic
effect of CASR (rs17251221) on susceptibility to nephrolithiasis is
still unclear.
The aim of the present study was to investigate whether the
CASR polymorphism (rs17251221) is associated with the develop-
ment of calcium nephrolithiasis. The number of renal stones is
related to the disease activity of nephrolithiasis; therefore, we
investigated the association between the CASR genetic poly-
morphism and the number of renal stones in patients with
nephrolithiasis.
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Subject recruitment
We conducted a case–control study from February 2009 to
December 2010 in Kaohsiung Medical University Hospital,
Kaohsiung, Taiwan. In total, 189 patients with calcium nephro-
lithiasis and 291 controls were included in the study. Calcium
nephrolithiasis was diagnosed on the basis of ultrasonographic and
radiographic findings. A 20-mL whole blood sample and a one-
spot midstream urine sample from the first voided urine were
collected from all subjects after they had fasted overnight. Blood
and urine samples were used to measure total calcium, phosphate,
uric acid, and creatinine levels. All urinary parameters were
corrected by using urinary creatinine levels. If stone specimens
were removed by surgery or obtained after medical treatment or
shock-wave lithotripsy, infrared spectroscopy (Spectrum RX I
Fourier Transform-Infrared System; Perkin Elmer, Shelton, CT,
USA) was used to confirm the composition of calcium-containing
stones [5]. Patients were excluded if they had a history of chronic
urinary tract infection, renal failure, chronic diarrhea, gout, renal
tubular acidosis, primary and secondary hyperparathyroidism, or
cancer. We also excluded anyone who had regularly taken
diuretics, vitamin D, or calcium supplements more than or equal
to 1 time per week within the 6 months leading up to the diagnosis
of calcium nephrolithiasis or the interview, because these
substances may have confounded our results. Further, in the
stone number analysis, patients with a single stone were grouped,
whereas patients with stone numbers over than one were grouped.
The 291 controls had normal urinalysis results, no history of
familial urinary stone disease, and no history of renal calcification
at health screening. All study subjects were residents of southern
Taiwan and provided the required written consent forms. The
study protocol conformed to the Declaration of Helsinki, and the
study was approved by the Institute Review Board of Kaohsiung
Medical University Hospital.
DNA extraction
Genomic DNA was extracted from whole blood samples by
using a standard protocol. Whole blood samples from patients and
controls were centrifuged at 3000 rpm for 10 min at 4uC. Buffy
coat was isolated from the blood samples. After lysing the red
blood cells in a lysis buffer, the samples were mixed with a cell lysis
buffer for several days. Protein precipitation solution was added to
precipitate the proteins. Finally, total genomic DNA was isolated
by precipitation with 95% isopropanol and 80% alcohol.
Genotyping CASR polymorphisms
A single nucleotide polymorphism (SNP) in CASR (rs17251221)
was selected on the basis of research findings reported by
O’Seaghdha et al [10]. The TaqMan Allelic Discrimination Assay
(Applied Biosystems, Foster City, CA, USA) was used for
genotyping. Briefly, the polymerase chain reaction (PCR) was
performed using the ABI7900 Thermal Cycler. The thermal cycle-
sequencing conditions were as follows: initial denaturation at 95uC
for 10 min, followed by 45 cycles of denaturing at 95uC for 15 s
and annealing and extension at 60uC for 1 min. Data was
measured and analyzed using the System SDS software version
1.2.3.
Statistical analysis
The distribution of genotypes was in Hardy–Weinberg
equilibrium (P.0.05) for both patients and controls. The statistical
differences between the patient and control groups or between the
multiple and single stone-episode groups in genotype and allele
frequency were analyzed by the chi-square test. Under certain
circumstances, Yates’ correction for the chi-square test was also
applied for a more stringent analysis. The relationship between
kidney stone diseases and multiplicity and CASR polymorphisms
was assessed by the odds ratio (OR). Quantitative variables were
expressed as the mean 6 standard deviation. The t-test was used
to compare the differences between the means of continuous
variables. A P value , 0.05 was considered statistically significant.
Statistical analyses were performed using SPSS, version 14.0
(SPSS Int., Chicago, IL, USA).
Results
Lack of association between the CASR rs17251221
polymorphism and the susceptibility to calcium
nephrolithiasis
In total, 480 subjects were enrolled in this study, including 189
patients with calcium nephrolithiasis and 291 controls. Men
accounted for 66.1% of the patients and 47.1% of the controls.
The age of the subjects ranged from 19 to 88 years. The mean age
of the patients was 52.6612.6 years; the controls had a similar age
distribution.
The genotype frequencies of the cases and controls were in
accordance with the Hardy–Weinberg equilibrium. Table 1 shows
the genotype frequencies of CASR polymorphism among subjects.
Since there was only 1 patient with the GG genotype, we classified
patients into 2 groups based on their genotypes, namely, the
GG+GA and AA groups. There were no significant differences in
the genotypes or allele frequencies of the SNP between the
controls and patients with calcium nephrolithiasis.
The genetic polymorphism (rs17251221) in CASR is
significantly associated with stone multiplicity in
nephrolithiasis patients
We further evaluated whether an association existed between
CASR and the characteristics of kidney stone patients, including
age, gender, number of stones, and frequency and family history of
stones. As shown in Table 2, the G allele of the polymorphism
rs17251221 is a risk allele that seems to have a dominant genetic
effect over the A allele, because the risk for stone multiplicity was
Table 1. Genotype frequencies for CASR rs17251221 and nephrolithiasis susceptibility.
Genotype
Case (%)
(n=189)
Control (%)
(n=291) Allele
Case (%)
(n=189)
Control (%)
(n=291)
Genotype
P value
Dominant
P value
Recessive
P value
Allelic
P value
rs17251221 GG 1 (0.5%) 0 (0.0%) G 15 (4.0%) 18 (3.1%) 0.440 0.600 0.214 0.467
AG 13 (6.9%) 18 (6.2%) A 363 (96.0%) 564 (96.9%)
AA 175 (92.6%) 273 (93.8%)
doi:10.1371/journal.pone.0025227.t001
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genotypic group (P=0.008; OR=4.79; 95% confidence interval,
1.44–15.92; Table 2). Similarly, a significant association between
rs17251221 and stone multiplicity was also observed when
we performed the more stringent Yates’ chi-square test
(P=0.013; Table 2).
Lack of association between rs17251221 polymorphism
of CASR and biochemical parameters in nephrolithiasis
patients
To understand the relationship between the rs17251221
polymorphism of CASR and clinical risk factors, we analyzed the
biochemical data, including the levels of urinary and serum
creatinine, uric acid, and calcium. None of the clinical parameters
reached a nominal significance level of 0.05 (Table 3), and subset
analysis on the cases did not yield any significant results (Table 4).
Discussion
Nephrolithiasis is one of the most common urologic diseases in
the developed countries. Chemical composition analysis of urinary
stones has indicated that calcium oxalate stones are the most
common and occur in approximately 75% to 80% of cases [11].
Consequently, factors that affect the serum levels of calcium ion
are important risk factors for calcium nephrolithiasis [12]. CASR
is a G-protein coupled receptor, which senses and sets the
extracellular calcium ion levels by regulating renal calcium
excretion and controlling parathyroid hormone secretion from
the parathyroid glands [13]. Evidence from gain- or loss-of-
function mutations in the CASR gene indicate that this gene plays a
critical role in calcium ion homeostasis [13]. In the kidney, CASR
prevents the reabsorption of divalent cations in the cortical thick
ascending limb and triggers the inhibitory actions of hypercalce-
mia on the urinary-concentrating mechanism, subsequently
leading to the prevention of kidney stone formation [14,15]. To
our knowledge, this is the first study to report a CASR
polymorphism (rs17251221) associated with the risk of stone
multiplicity in calcium nephrolithiasis.
Nephrolithiasis research has focused on biochemical or
metabolic alterations in local urinary constituents leading to stone
formation. However, abnormalities in the chemical composition of
urine alone do not explain many aspects of nephrolithiasis urinary
stone disease [11]. Recent evidence from genome-wide association
studies suggests that the rs17251221 polymorphism in CASR is
strongly associated with total serum calcium levels [9,10]. Indeed,
a genome-wide meta-analysis showed that common CASR variants
modulate serum calcium levels in the adult general population
[9,10]. In agreement with the findings of the above-mentioned
Table 2. Association analysis between CASR rs17251221 and subgroups of 189 patients with kidney stone.
CASR genotype P value
OR
(95% CI) P value
a
GG+AG
(n=14)
AA
(n=175)
Age, Mean 6 SD 51.7610.0 52.6612.8 0.798
Gender, Male (%) 8 (57.1%) 117 (66.9%) 0.559
Stone numbers (%)
Multiple 10 (71.4%) 60 (34.3%) 0.008*4 . 7 9
(1.44–15.92)
0.013*
Single 4 (28.6%) 115 (65.7%)
Stone frequency (%)
Recurrence 7 (50.0%) 62 (35.4%) 0.387
Non- recurrence 7 (50.0%) 113 (64.6%)
Family history (%)
Positive 3 (21.4%) 45 (25.7%) 1.000
Negative 11 (78.6%) 130 (74.3%)
*Significant (P,0.05) values are in bold.
aYates’ correction for chi-square test.
doi:10.1371/journal.pone.0025227.t002
Table 3. Association analysis between CASR rs17251221 and clinical biochemical data in patients with calcium kidney stone.
SNP Genotype
Urine
Creatinine
(mg/dl)
Urine
pH
Urine
Calcium
(mg/dl) UCa/UCr
a
Urine
Uric Acid
(mg/dl) UUA/UCr
b
Serum
Creatinine
(mg/dl)
Serum
Calcium
(mg/dl)
Serum
Uric Acid
(mg/dl)
rs17251221 GG+AG 65.6650.0 5.960.6 9.063.4 0.260.1 29.2619.7 0.961.5 1.060.3 8.960.5 6.061.8
AA 85.2659.6 6.160.6 11.467.5 0.260.1 39.0625.1 0.560.2 1.160.8 8.760.7 6.361.6
P value 0.2505 0.2481 0.0713 0.6259 0.1706 0.3686 0.2784 0.5281 0.6277
aUrinary calcium-Creatinine ratio (UCa/UCr).
bUrinary uric acid-Creatinine ratio (UUA/UCr).
doi:10.1371/journal.pone.0025227.t003
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an association between the rs17251221 minor G allele and the
disease activity of calcium nephrolithiasis. However, we did not
observe a significant association between higher levels of serum or
urine calcium and this SNP in a Taiwanese population. We
attribute this finding to the low statistical power of using a limited
number of subjects (only 169 cases with clinical biochemical data).
Additionally, when testing for the effects of the CASR genotype on
clinical biochemical parameters we did not use a control group.
The availability and use of data from the controls would have
strengthened our observation. Another possible explanation for
our results is the different genetic backgrounds of the populations
and the phenotypic heterogeneity of nephrolithiasis. Our findings
still need to be replicated in a larger sample size.
CASR gene mutations have been implicated in several rare
familial genetic disorders. For instance, the gain-of-func-
tion mutations E128A (Glu128Ala; rs121909260; MIM
#601199.0004) and T151M (Thr151Met; rs104893694; MIM
#601199.0012) cause an autosomal dominant form of hypocal-
cemia (MIM #146200), whereas R990G (Arg990Gly; rs1042636)
is a gain-of-function mutation that was reported to predispose
patients to primary hypercalciuria and kidney stone disease
[10,16]. Interestingly, the R990G variant increases patient
susceptibility to primary hypercalciuria in patients with kidney
stones [16]. In contrast, loss-of-function mutations in FHH result
in the inactivation of CASR and subsequent hypercalcemia and
hypermagnesemia [19]. O’Seaghdha et al have indicated that the
minor G allele of rs17251221 was associated with higher serum
calcium and magnesium levels and suggested that the causal G
variant may underlie a reduction in CASR activity [10]; this
finding also suggested a role of CASR in regulating extracellular
calcium concentrations. However, a search of the Ensembl
(University of California, Santa Cruz) genome browser and
ConSite databases for regulatory elements around the genomic
region corresponding to rs17251221 did not reveal any functional
regulatory elements. O’Seaghdha et al pointed out that there was
another coding SNP in this gene, rs1801725 (A986S), which has
been detected among families with FHH and in the general
population [10]. Thus, further studies to test the association
between rs1801725 and nephrolithiasis may provide a better
understanding of this disease.
In conclusion, our data showed a significant association between
rs17251221 and stone multiplicity in nephrolithiasis patients,
suggesting that rs17251221 is as a susceptibility marker for stone
multiplicity in nephrolithiasis. Moreover, this is the first evidence
that the risk of developing renal stones was greater in
nephrolithiasis patients having the G allele of rs17251221 than
those having the A allele.
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